1. Home
  2. TLX vs CNS Comparison

TLX vs CNS Comparison

Compare TLX & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TLX
  • CNS
  • Stock Information
  • Founded
  • TLX 2015
  • CNS 1986
  • Country
  • TLX Australia
  • CNS United States
  • Employees
  • TLX N/A
  • CNS N/A
  • Industry
  • TLX Biotechnology: Pharmaceutical Preparations
  • CNS Investment Managers
  • Sector
  • TLX Health Care
  • CNS Finance
  • Exchange
  • TLX Nasdaq
  • CNS Nasdaq
  • Market Cap
  • TLX 4.0B
  • CNS 3.9B
  • IPO Year
  • TLX N/A
  • CNS 2004
  • Fundamental
  • Price
  • TLX $9.51
  • CNS $73.85
  • Analyst Decision
  • TLX Strong Buy
  • CNS Hold
  • Analyst Count
  • TLX 3
  • CNS 3
  • Target Price
  • TLX $22.33
  • CNS $82.00
  • AVG Volume (30 Days)
  • TLX 217.0K
  • CNS 244.9K
  • Earning Date
  • TLX 01-01-0001
  • CNS 10-15-2025
  • Dividend Yield
  • TLX N/A
  • CNS 3.36%
  • EPS Growth
  • TLX N/A
  • CNS 23.33
  • EPS
  • TLX 0.04
  • CNS 3.15
  • Revenue
  • TLX $664,225,558.00
  • CNS $543,579,000.00
  • Revenue This Year
  • TLX N/A
  • CNS $7.32
  • Revenue Next Year
  • TLX N/A
  • CNS $8.15
  • P/E Ratio
  • TLX $298.01
  • CNS $23.48
  • Revenue Growth
  • TLX 55.35
  • CNS 11.54
  • 52 Week Low
  • TLX $9.48
  • CNS $68.99
  • 52 Week High
  • TLX $30.36
  • CNS $110.67
  • Technical
  • Relative Strength Index (RSI)
  • TLX 31.15
  • CNS 46.52
  • Support Level
  • TLX $12.12
  • CNS $71.31
  • Resistance Level
  • TLX $12.58
  • CNS $77.18
  • Average True Range (ATR)
  • TLX 0.45
  • CNS 1.96
  • MACD
  • TLX 0.01
  • CNS 0.01
  • Stochastic Oscillator
  • TLX 0.98
  • CNS 37.63

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.

Share on Social Networks: